Sodium/glucose cotransporter: Difference between revisions
Jump to navigation
Jump to search
Michal Harel (talk | contribs) New page: ==Your Heading Here (maybe something like 'Structure')== <StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''> This is a default text for you... |
Michal Harel (talk | contribs) No edit summary |
||
| (20 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
<StructureSection load='8hez' size='340' side='right' caption='Human glycosylated SGLT2 (cyan) complex with PDZK1-interacting protein (green), drug dapagliflozin and Na+ ion (PDB code [[8hez]])' scene='10/1042600/Cv/1'> | |||
<StructureSection load=' | == Function == | ||
'''Sodium/glucose cotransporter''' (SGLT) is responsible for glucose absorption across membranes. SGLT1 and SGLT2 which are expressed in different tissues, have similar active sites but differ in their non-active site structures. '''SGLT1''' is responsible of glucose absorption in the small intestine and '''SGLT2''' in kidney<ref>PMID:26125647</ref>. | |||
== Disease == | == Disease == | ||
Mutations in SGLT1 cause malabsorption of glucose and galactose<ref>PMID:31081587</ref>. | |||
== Relevance == | == Relevance == | ||
SGLT2 inhibitors aid in hypertension, acute cardiac failure, bradycardia, acute pulmonary oedema, asthma, bronchitis and | SGLT2 inhibitors aid in hypertension, acute cardiac failure, bradycardia, acute pulmonary oedema, asthma, bronchitis and COPD<ref>PMID:36819350</ref>. | ||
== Structural highlights == | == Structural highlights == | ||
The drug Dapagliflozin contains a <scene name='10/1042600/Cv/5'>glucose moiety which stacks against residue Y290</scene> of SGLT2. The <scene name='10/1042600/Cv/6'>glucose moiety forms multiple H-bonds</scene> to SGLT2<ref>PMID:38057552</ref>. Water molecule is shown as red sphere. | |||
See also: | |||
*[[Canagliflozin]] | |||
*[[Dapagliflozin]] | |||
*[[Empagliflozin]] | |||
==3D structures of sodium/glucose cotransporter== | |||
[[Sodium/glucose cotransporter 3D structures]] | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category:Topic Page]] | |||
Latest revision as of 12:25, 13 August 2024
FunctionSodium/glucose cotransporter (SGLT) is responsible for glucose absorption across membranes. SGLT1 and SGLT2 which are expressed in different tissues, have similar active sites but differ in their non-active site structures. SGLT1 is responsible of glucose absorption in the small intestine and SGLT2 in kidney[1]. DiseaseMutations in SGLT1 cause malabsorption of glucose and galactose[2]. RelevanceSGLT2 inhibitors aid in hypertension, acute cardiac failure, bradycardia, acute pulmonary oedema, asthma, bronchitis and COPD[3]. Structural highlightsThe drug Dapagliflozin contains a of SGLT2. The to SGLT2[4]. Water molecule is shown as red sphere. See also: 3D structures of sodium/glucose cotransporterSodium/glucose cotransporter 3D structures
|
| ||||||||||
ReferencesReferences
- ↑ Poulsen SB, Fenton RA, Rieg T. Sodium-glucose cotransport. Curr Opin Nephrol Hypertens. 2015 Sep;24(5):463-9. PMID:26125647 doi:10.1097/MNH.0000000000000152
- ↑ Dominguez Rieg JA, Rieg T. What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition. Diabetes Obes Metab. 2019 Apr;21 Suppl 2(Suppl 2):43-52. PMID:31081587 doi:10.1111/dom.13630
- ↑ Jasleen B, Vishal GK, Sameera M, Fahad M, Brendan O, Deion S, Pemminati S. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk. Cureus. 2023 Jan 18;15(1):e33939. PMID:36819350 doi:10.7759/cureus.33939
- ↑ Hiraizumi M, Akashi T, Murasaki K, Kishida H, Kumanomidou T, Torimoto N, Nureki O, Miyaguchi I. Transport and inhibition mechanism of the human SGLT2-MAP17 glucose transporter. Nat Struct Mol Biol. 2024 Jan;31(1):159-169. PMID:38057552 doi:10.1038/s41594-023-01134-0